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Abstract
Introduction: TNF-related apoptosis-inducing ligand (TRAIL) is a death ligand
and also a member of the TNF superfamily. We aimed to investigate the possible
relationship between TRAIL and breast cancer. Here, we report the results of the
first association study on genetic variation in the TRAIL gene and its effect on
breast cancer susceptibility and prognosis. 
Material and methods: A C/T polymorphism at 1595 position in exon 5 of the
TRAIL gene was genotyped in a Turkish breast cancer case-control population
including 53 cases (mean age: 55.09 ±11.63 years) and 57 controls (mean age:
57.17 ±17.48 years) using polymerase chain reaction–restriction fragment length
polymorphism (PCR-RFLP) analysis. 
Results: There were no differences in the distribution of TRAIL genotypes and
frequencies of the alleles in the breast cancer patients and controls.
A heterozygous TRAIL CT polymorphism in exon 5 was present in 8.3% of tumour
stage III-IV and 48.8% of stage I-II patients, and in 42.1% of controls. The reduced
frequency of this genotype in patients who had advanced tumour stage was
statistically significant (p = 0.017). 
Conclusions: Our findings indicate that genetic variants of TRAIL at position 1595
in exon 5 might be associated with progression of breast cancer.
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Introduction
The contribution of genetic factors to the development of breast cancer,
one of the most common human neoplasms, accounting for approximately
one quarter of all cancers in females, has been verified by numerous genetic
and epidemiological case-control studies [1]. Apoptosis, or programmed cell
death, plays an important role in cell proliferation control throughout
embryonic and adult life. The role of apoptosis in oncogenesis is currently
being studied intensively in several cancers [2]. It is known that defects in
apoptotic (programmed cell death) mechanisms play an important role in
pathogenesis and progression of breast cancer. Some studies have reported
that expression of multiple apoptosis-modulating proteins in breast cancer
cell lines and primary tumours suggests complexity in the regulation of
apoptosis in the neoplasms of mammary epithelial origin. But, relatively little
is known about which apoptosis-regulating genes are expressed in tumours
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mechanisms underlying these effects [3]. Tumour
necrosis factor (TNF)-related apoptosis-inducing factor
(TRAIL) is a death ligand, a member of the TNF/nerve
growth factor superfamily, and preferentially induces
apoptosis in tumour cells but not in normal cells. It is
known that TRAIL selectively kills cancer cells without
causing any harm to normal cells [4, 5]. However,
a considerable proportion of human tumours (60%)
appear to be TRAIL resistant and the mechanism of
TRAIL resistance is still unclear [6, 7]. Five TRAIL
receptors, which are called TRAIL-R1 or death receptor
4 (DR4), TRAIL-R2 or DR5, TRAIL-R3 or decoy receptor
1 (DcR1), TRAIL-R4 or DcR2, and osteoprotegerin
(OPG), have been described [8]. It is known that only
two of the TRAIL receptors, TRAIL-R1 and TRAIL-R2,
contain functional death domains capable of inducing
apoptosis [6]. When TRAIL interacts with one of these
five receptors, it can induce or inhibit apoptosis,
depending on which receptor is utilized [9-13]. TRAIL
is located at chromosome 3q26. It is composed of five
exons and encodes a 1.77-kb mRNA. Four single
nucleotide polymorphisms (SNPs) in the 5’-regulatory
region [14] and four SNPs in the 3’-untranslated region
(3’UTR) [15,16] of the TRAIL gene have been described.
It has also been reported that there is a highly
polymorphic region in the TRAIL promoter with four
SNPs located in a 111 base pair (bp) spanning
sequence between nucleotides 707 and 597 upstream
of the transcriptional start site. However, it did not
influence TRAIL expression in patients with multiple
sclerosis [17]. On the basis of the mRNA sequence,
three SNPs have been identified in the 3’UTR at
nucleotides 1525, 1588, and 1595 of the TRAIL gene
[16]. There have been no studies on the effect of TRAIL
1595 C/T polymorphism in human tumours. The aim
of the present study was to analyse the relationships
between TRAIL gene polymorphism in the 3’-untra  n  -
slated region of exon 5 at position 1595 and disease
susceptibility and prognostic implications in 66 Turkish
patients with breast cancer. 
Material and methods
Study participants 
Fifty-three breast cancer patients (mean age 55.09
±11.63 years; age range 31-78 years) and 
57 healthy females (mean age 57.17 ±17.48 years; age
range 32-87 years) were included in the study. All
subjects provided written informed consent before
they participated in the study. Participants were
selected from Istanbul Research and Education
Hospital, Surgery Clinic. Questionnaires, medical
records, and pathological reports were received to
confirm the diagnosis and cancer status. The control
subjects were randomly selected among volunteers
and were not taking any regular medication at the
time of the study. The samples were collected before
any chemotherapeutic or radiation therapy treatment
had been started. Blood samples were taken from
patients who had pathological diagnosis and had not
undergone blood transfusion. A standardized que  -
stionnaire was administered to collect data
concerning age, family history of breast cancer, and
family history of any kind of cancer for our breast
patients from whom we obtained blood samples.
Pathological staging information on all breast cancer
diagnoses were confirmed by manual review of the
pathology reports and clinical charts. Nodal status
was categorized as no regional lymph nodes affected
(N0) or at least one nodal metastasis. This study was
approved by the Medical E  thics Committee of Istanbul
Medical Faculty.
Isolation of DNA. Blood specimens were collected
into tubes containing EDTA. DNA was isolated from
white blood cells by sodium dodecyl sulphate lysis,
proteinase K digestion, ammonium acetate extraction
and ethanol precipitation [18].
Polymerase chain reaction (PCR) for TRAIL gene.
For the TRAIL 1595 C/T polymorphism forward primer
5’-TGA GCA CTA CAG CAA ACA TGA-3’ and the reverse
primer 5’-GCA CCA CTA AAA GAT CGC AGT-3’ were
used [19] at a concentration of 10 pmol/μl for each
primer. The PCR reaction mixture contained 150 ng
DNA template, 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-
HCl (pH 8.4), 200 μM each of deoxynucleotide
triphosphate (MBI Fermentas, Vilnius, Lithuania), and
2 units of Taq DNA polymerase (MBI Fermentas,
Vilnius, Lithuania). 
The DNA was denatured at 95°C for 5 min, and
temperature cycling was set at 94°C for 1 min, 56°C
for 1 min and 72°C for 1 min for 30 cycles, followed
by a final extension at 72°C for 10 min. The 391-base
pair PCR product was digested by RsaI (MBI
Fermentas) at 37°C for 2.5 hours. After RsaI digestion
of this PCR product, we detected two fragments
having 59 and 332 bp (C allele) or three fragment
having 59, 146, and 186 bp (T allele) (Figure 1).
Figure 1. Direct visualization of PCR-RFLP typing pattern
of TRAIL genotypes by ethidium bromide staining.
A 391-base pair TRAIL 1595 C/T fragment was
amplified, cleaved with RsaI, and ele  ctrophoresed 
on a 3% agarose gel. Results from seven representa  -
tive breast cancer patients are shown. Lane 1:
pUC19/Msp1 marker; lane 2: TT homozygote; lane 3, 4:
CC homozygote; lane 5: CT heterozygotes; lane 6: 
CC homozygotes; lane 7: TT homozygotes; lane 8: 
CT heterozygotes
1234 5 6 78
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light and a photo was taken with a Polaroid camera.
In the case of any doubt concerning the allele, the
sample was analysed once again.
Statistical analysis. All statistical analyses were
carried out using SPSS version 7.5 for Windows
(SPSS Inc, Chicago, USA). Numeric values were
analysed by Student’s t-test. Differences in
characteristics between breast cancer patients and
controls, as well as disparities in genotype and allele
frequencies, were assessed with the chi-square test.
Odds ratios (ORs) and 95% confidence intervals
(95% CI) were calculated to estimate the risk for
breast cancer. P-values less than 0.05 were
considered statistically significant.
Results
In the present study, we determined TRAIL 1595
C/T polymorphism in 53 breast cancer patients and
57 controls. Genotypes and allele frequencies for
TRAIL 1595 C/T in breast cancer patients and controls
are listed in Table I. With the use of the χ2 test, we
found that differences in TRAIL 1595 C/T genotype
and allele frequencies between breast cancer patients
and controls were not statistically significant 
(p = 0.896, p = 0.830, respectively). Distribution of
TRAIL 1595 C/T genotypes according to clinical
parameters and tumour characteristics of breast
cancer patients are summarized in Table II. Patients
with T3/T4 stage breast carcinoma showed a lower
prevalence of TRAIL CT (8.3%) genotype when
compared to patients with T1/T2 stage (48.8%) breast
cancer (p = 0.017; OR: 0.171 95% CI 0.025-1.145).
Among breast cancer patients, there was no
significant association between the TRAIL 1595 C/T
genotypes and age, family history of breast cancer,
oestrogen receptor, or progesterone receptor. The
genotype distributions of our patients and controls
were in line with the Hardy-Weinberg equilibrium 
(p = 0.580 for patients, p = 0.960 for controls).
Discussion
TRAIL selectively killed cancer cells without causing
any harm to normal cells [5]. TRAIL can induce
apoptosis in a broad range of human cancer cell lines
including breast cancer cell lines [20, 21]. SNPs present
along the TRAIL gene have been extensively studied
in multiple sclerosis [17, 19]. However, similar studies
in cancer are lacking. An important gene
polymorphism in TRAIL, reported by Gray et al. [16],
has been identified in the 3’UTR at nucleotide 1595.
The frequency of C allele at position 1595 for
Caucasians and American Africans was 0.712 and
0.842, respectively. Kikuchi et al. [19] reported an
association between the TRAIL 1595 C/T gene
polymorphism and multiple sclerosis susceptibility in
Japanese patients, and they also reported that the
frequency of the C allele was 0.592 in a Japanese
population. In our study the frequency of the C allele
at position 1595 was 0.702 in Turkish women. This
was similar to Gray’s findings [16]. The present study
is the first preliminary report showing a relationship
between breast cancer and TRAIL 1595 C/T gene
polymorphism. In our study, we did not find any
significant difference in the genotype distribution
between patients and controls. In 2009, it was
reported that TRAIL TT genotype was associated with
a lower risk of fatty liver diseases (FLD) and a less
severe form of steatosis in non-alcoholic fatty liver
disease (NAFLD) patients in a Chinese population [22].
Yan et al. [22] found that NAFLD and AFLD patients
also show significantly lower frequencies of 1595 TT
genotype than healthy controls not abusing alcohol.
They also measured soluble TRAIL (sTRAIL) levels in
NAFLD and healthy subjects. They showed that
Chinese individuals with TT genotype of TRAIL at 1595
position in 3’UTR have a lower susceptibility to FLD,
and sTRAIL con  centrations in non-alcoholic FLD
(NAFLD) patients were significantly higher than those
of controls. They hypothesized that TRAIL gene
polymorphism at this position might affect TRAIL’s
function in lipid metabolism [22]. Ganten et al. [23]
determined the expression pattern of all surface-
bound TRAIL receptors and their prognostic clinical
value. They suggested that TRAIL receptor ex  pression
profile may aid in defining which breast cancer
patients have a higher risk of lymph node metastasis
and worse overall survival. It has been suggested that
TRAIL also induces apoptosis in a variety of tumour
Genotype Patients,  % Controls,% O R (95 % CI) P value
n = 53 n = 57
CC 26 49.1 28 49.1 0.999 (0.682-1.462) 0.994
CT 21 39.6 24 42.1 0.941 (0.600-1.477) 0.791
TT 6 11.3 5 8.8 1.291 (0.418-3.981) 0.656
Alleles
C 73 68.9 80 70.2 – 0.83
T 33 31.1 34  29.8          –
The p-value was obtained by χ2 test. #Odds ratio for genotype was calculated as selected genotype vs. other genotypes. 
OR indicates crude odds ratio
Table I. Genotypes and allele frequencies for TRAIL 1595 C/T in breast cancer patients and controls 
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breast xenografts [24, 25]. Preclinical testing of TRAIL
in combination with conventional che  motherapeutic
agents has demonstrated significant inhibition of
tumour growth in a prostate cancer in vivo model
[26]. Recently, Pal et al. [27] have reported that
a promoter SNP of TRAIL functionally modulates the
gene expression, and they advise considering the 
-716 TRAIL SNP status in patients undergoing TRAIL
therapy. They showed that high TRAIL expressing
individuals with -716 CC genotype are at a greater risk
of developing tumour, which can be inferred from our
observation of the predominance of the major
genotype, CC, in the initial stages of breast cancer,
ER/PR positive cases and small tumour size [27].
The major finding of the present study was that
in breast cancer patients who have TRAIL CT
genotype at position 1595 in 3’UTR, the tumour was
in a non-advanced stage. At present, the influence
of TRAIL gene polymorphisms on the functions of
the TRAIL protein and on its involvement in the
development and progression of breast cancer is
still unclear. It has been suggested that complex
and heterogeneous genetic alterations are involved
in the aetiology of breast tumourigenesis. Analysis
of multiple signalling pathways would be more
informative and useful in both diagnosis and
prognosis of breast tumours [28]. We evaluated, for
the first time, the role of the TRAIL polymorphism
at position 1595 in 3’UTR in breast cancer risk and
progression by genotyping 53 cases and 57 healthy
controls drawn from the Turkish population.
Additional studies are needed to assess the role of
TRAIL polymorphism in the risk and progression of
breast cancer.
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N % CC (%) CT (%) TT (%)
Age ≤ 45 years 12 22.6 4 (33.3) 7 (58.3) 1 (8.3)
Age > 45 years 41 77.4 22 (53.7) 14 (34.1) 5 (12.2)
Family history of breast cancer
Yes 12 22.6 8 (66.7) 3 (25) 1 (8.3)
No 41 77.4 18 (43.9) 18 (43.9) 5  (12.2)
Tumour (T) stage
T1 14 26.4 7 (50) 6 (42.9) 1 (7.1)
T2 25 47.2 11 (44) 13 (52) 1 (4)
T3 10 18.9 5 (50) 2 (20) 3 (30)
T4 4 7.5 3 (75) 0 (0) 1 (25)
Lymph node status
N0 14 26.4 7 (50) 6 (42.9) 1 (7.1)
N1 23 43.4 12 (52.2) 9 (39.1) 2 (8.7)
N2 13 24.5 6 (46.2) 5 (38.5) 2 (15.4)
N3 3 5.7 1 (33.39) 1 (33.3) 1 (33.3)
Distant metastasis 
(+) 3 5.7 2 (66.7) 1 (33.3) –
(–) 50 94.3 24 (48) 20 (40) 6 (12)
Oestrogen receptor
(–) 6 13.0 4 (66.7) 2 (33.3) –
(+) 40 87.0 18 (45) 17 (42.5) 5 (12.5)
Progesterone receptor
(–) 7 15.2 4 (57.1) 3 (42.9) –
(+) 39 84.8 18 (46.2) 16 (41) 5 (12.8)
Table II. Distribution of TRAIL 1595 C/T genotypes according to clinical parameters and tumour characteristics of
breast cancer patients
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